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Table 1
Day Whole Blood Chimerism CD4(cells/uL) CD8(cells/uL) CD56(cells/uL)
PG IG p PG IG p PG IG p PG IG p
30 91.821.8 93.419.8 0.765 25.848.3 76.2592.97 0.198 6.410.4 105.099.5 0.142 146.7104.1 66.877.8 0.189
100 94.27.8 95.84.6 0.399 51.038.1 113.084.1 0.001 77.2116.5 203.5258.1 0.020 256.8138.4 217.1125.1 0.270
180 93.06.2 92.712.1 0.911 148.8134.3 283.6163.6 0.003 156.0146.3 399.8358.9 0.004 252.9148.7 260.2132.5 0.857
365 89.910.0 91.915.7 0.574 583.7346.8 784.1589.1 0.280 593.9564.9 599.6367.4 0.974 350.8377.0 285.0204.5 0.508
In the UCB sub-analysis of PG pts (n¼12), compared to remaining donor sources (n¼25), a higher incidence of viral disease (33% vs. 16%, p¼0.4), viral reactivation
(58% vs. 32%, p¼0.1), and GF (p¼0.0001) and TRM (p¼0.008) was noted, respectively. The 1 yr OS in the UCB cohort was 67%, p¼0.03.
Table 1
Relapsed (n¼22) Non-relapse
(n¼41)
Patient Characteristics
Median Age at Transplant (yrs) 10 7.2
Gender
M 12 29
F 10 12
Ethnicity
Caucasian 9 19
Hispanic 10 12
Others 3 10
De novo AML 15 34
Secondary AML/MDS 7 7
Risk Stratiﬁcation
High Risk 13 27
Intermediate Risk 9 12
Unknown 0 2
Remission Pre HCT
CR1 14 17
Abstracts / Biol Blood Marrow Transplant 21 (2015) S206eS239S210(Css- 600-900ng/ml)/Fludarabine (160-180mg/m2)/Alemtu-
zumab (45-54mg/m2) regimen were included. Pts received
Alemtuzumab either Days -6 to -2 (proximal group [PG]) or
from Days -12 to -9 (intermediate group [IG]).
Results: 37 pts were included in PG and 39 in IG. Donor
Sources in PGwere related¼20 (54%) and unrelated¼17 (46%)
vs. 14 (36%) and 25 (64%) in IG, respectively (p<0.001). Five
pts (14%) in PG had an underlying malignancy vs 2 pts (5.1%)
in IG. Stem Cell Sources in PG were: BM¼18 (49%), PBSC¼4
(11%), related CB¼3 (8%), unrelated CB (UCB)¼12(32%); in IG,
BM¼27 (69%), PBSC¼12 (31%). Tomaximize the homogeneity,
the UCB in the PG group were analyzed separately. Kinetics of
immune reconstitution are in Table 1 (excludes UCB). The
incidence of viremia in PG vs. IG was comparable, p¼0.3.
Signiﬁcantly higher CMV disease was seen in PG vs. IG
(16.7% vs. 2.6%, p¼0.03), respectively. Higher TRM was seen
in IG vs. PG: 12.8% vs. 0%(p¼0.06), respectively. Rates of GF
were comparable (p¼1), while PG had a higher incidence of
grade II-IV acute GVHD (32% vs. 12.8%, p¼0.1). The OS at 1
year in PG was 96% vs. 79.5%(p¼0.07) in IG.
Discussion: Pts receiving PG had delayed immune recon-
stitution which did not impact OS. Chimerism was compa-
rable between the two groups. The optimal timing of
Alemtuzumab administration remains unclear; however,
UCB is associated with inferior outcomes. Larger studies
evaluating outcomes and health care utilization/cost are
needed.MDS 3 9
CR2 5 13
Unknown 0 2
Transplant Characteristics
Median Time to Transplant
(days)
108 (55-492) 139 (16-1349)
Donor
Matched Related Donor 11 12
Alternative Donor 11 29
Stem Cell Source
PBSC 16 24
BM 5 6
Cord 1 11
Conditioning
MAC 13 32
RIC 9 9
GVHD Prophylaxis
Cyclosporine based 21 40
Tacrolimus based 1 1
Median Cell Doses
TNC dose (x108/kg) 7.3 (0.95-12.6) 5.7 (0.34-30.7)
CD34+ dose (x106/kg) 6.0 (2.45-13.0) 5.9 (0.04-22.5)
MNC dose (x108/kg) 5.9 (0.14-12.5) 2.8 (0.18-11.5)
CD3 dose (x108/kg) 2.3 (0.15-5.8) n¼11 2.6 (0.27-390)
n¼16
Median Engraftment
ANC > 500 13.5 (10-30) 12.5 (6-50)
Plt > 20K 16 (0-36) 16 (0-90)
Mixed T-cell Chimerism 14 13
Transplant Complications
CMV 4 5
aGVHD > grade 2 4 10
cGVHD 4 16
Death 16 14277
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Background: Hematopoietic Cell Transplant (HCT) is often
curative for patients with myelodysplastic syndrome (MDS)
or Acute Myeloid Leukemia (AML). However 20-60% of pa-
tients relapse post HCT. We aim to identify factors that pre-
dict relapse after HCT.
Methods: From 2002-2014, 63 pediatric patients underwent
HCT for AML or MDS at our institution with reduced intensity
conditioning (RIC) or myeloablative conditioning (MAC) 22 of
whom relapsed. A retrospective review of patients who did or
did not relapse was performed comparing clinical variables,chimerism, cytogenetics, ﬂow cytometry and morphology at
diagnosis, pre HCT, day 100 post HCT and at relapse.
Results: Table 1 describes patient variables. Median time
to relapse was D 210 post-HCT (20-1644). Most relapsed
early post HCT (54%, 100-365 days p¼0.008). Relapse was
more frequent in patients receiving RIC versus MAC (50%,
29%, p¼0.15) and with matched related donors versus
Abstracts / Biol Blood Marrow Transplant 21 (2015) S206eS239 S211alternative donors (48%, 28%, p¼0.2). Both groups were
comparable with respect to disease risk, cytogenetics, graft
composition, and post HCT complications (>Gr 2 acute
graft versus host disease (GVHD), CMV viremia), except for
engraftment syndrome which was more frequent in the
non-relapse group. Relapsed cohort had a higher incidence
(63% vs 31%) of partial T-cell chimerism, speciﬁcally lower
T-cell chimerism at engraftment and D30 (75%, 74.5%)
compared to non relapsers (90.5% and 94%), but was not
statistically signiﬁcant (p¼0.5 and p¼0.3).
Conclusions: Relapse is a major cause of mortality in pa-
tients that undergo HCT for AML/MDS. Relapse frequently
occurred early post HCT, in patients receiving RIC regimens
or those with partial donor T-cell chimerism at engraftment
and D30 post HCT in this small cohort. Further analyses are
ongoing to identify a subgroup of patients in whom pre-
emptive intervention is warranted.278
Successful Treatment of Secondary Graft Failure
Following Unrelated Cord Blood Transplant with
Hematopoietic Growth Factors in a Patient with Fanconi
Anemia
David Buchbinder, Loan Hsieh, Arash Mahajerin,
Geetha Puthenveetil, Amit Soni, Diane Jean Nugent. Children’s
Hospital of Orange County, Orange, CA
Background: Graft failure following unrelated cord blood
transplantation (UCBT) in patients with Fanconi anemia is
associated with signiﬁcant mortality. Second transplantation
may be considered; however, the limited toxicity proﬁle of
hematopoietic growth factors makes them an option for the
treatment of graft failure. We describe a 7-year-old female
with Fanconi anemia and marrow failure treated with UCBT
utilizing a 6/6 HLA matched cord blood unit. The course was
complicated by secondary graft failure treated with he-
matopoietic growth factors including granulocyte colony
stimulating factor (GCSF), erythropoietin (EPO), and romi-
plostim with reversal of pancytopenia and transfusion
dependence. The use of hematopoietic growth factors in the
treatment of secondary graft failure following UCBT in pe-
diatric patients with Fanconi anemia might be considered as
alternative to re-transplantation.
Methods: The preparative regimen included total body
irradiation (3 Gy), ﬂudarabine (35 mg/m2/day x 4 days),
cyclophosphamide (10 mg/kg/day x 4 days), and thymoglo-
bulin (3 mg/kg/day x 4 days). Graft-versus-host disease
(GVHD) prophylaxis included cyclosporine and mycophe-
nolate mofetil. A total of 11.6 x 10
ˇ
7 TNC/kg and 0.9 x 10
ˇ
6
CD34/kg cell were infused. Engraftment occurred on Day +18.
No evidence of GVHD was noted and immunosuppression
was discontinued on Day +110. Post-HSCT complications
included: mucositis, respiratory syncitial virus infection,
adenovirus viremia, hemorrhagic cystitis, and cytomegalo-
virus (CMV) reactivation. On Day +79 CMV reactivation
reoccurred and valganciclovir was started on Day +87. On
Day +103 leukopeniawas noted and Bactrimwas stopped. On
Day +110, CMV was undetectable and valganciclovir was
stopped due to evolving cytopenias.
Results: Transfusionwith packed red blood cell and platelets
were provided. A bone marrow examination demonstrated a
hypocellular marrow (< 5%) and a normal cytogenetic
evaluation. On Day +188, engraftment analysis using whole
blood still demonstrated 98% donor DNA suggesting that the
few remaining stem cells were of donor origin. In order
to avoid the toxicity associated with second transplant, GCSF
(5 mcg/kg/day), romiplostim (10 mcg/kg/week), and EPO(150 units/kg/dose three times per week), was started on Day
+114, +117, and Day +119; respectively. By Day +130 the
absolute neutrophil count was > 500/uL and platelet count
was > 25,000/uL. By Day +149, the cytopenias and need for
transfusion support had resolved off of hematopoietic
growth factors.
Conclusion: To our knowledge, this is the ﬁrst description of
a successful application of hematopoietic growth factors as
initial therapy in a patient with secondary graft failure
following UCBT for Fanconi anemia. We found that the use of
hematopoietic growth factors to be an alternative to the
morbidity and mortality associated with the use of second
transplantation.279
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Despite signiﬁcant improvement in outcomes for patients
with pediatric non-Hodgkin lymphomas (NHL), relapsed
disease is associated with poor long-term survival. He-
matopoietic stem cell transplant (HSCT) is used to improve
outcome in this setting but there are limited data in pediatric
patients with NHL.
Methods: We now report on 29 pediatric patients who un-
derwent allogeneic HSCT at our institute between 1999-
2013.
Results: There were 16 male and 13 female patients and the
median age was 14 years (range 5-23 years). Histological
categories were anaplastic large cell lymphoma (ALCL)
(n¼9), lymphoblastic lymphoma (LL) (n¼8), diffuse large B
cell lymphoma (DLBCL) (n¼7), other B cell lymphomas
(Burkitt’s lymphoma¼1, Small cell, non-Burkitt’s high grade
lymphoma¼1, and T-cell rich, B-cell lymphoma¼1), and
other T-cell lymphoma (Stem cell myeloproliferative/T-cell
lymphoma¼1, and hepatosplenic T-cell lymphoma¼1). 9
patients received grafts from matched-related donors, 8
from matched-unrelated donors, 8 from mismatched-unre-
lated donors and 4 from haploidentical donors. 21/29
received a myeloablative conditioning regimen (MAC) while
8/29 patients received a reduced intensity conditioning
regimen (RIC). At the time of transplant, 23/28 patients were
in complete remission (CR¼10) or partial remission (PR¼13),
while 5/28 patients had persistent or progressive disease
based on standard established criteria. The 3eyear relapse
free survival (RFS) was 59% (95%CI: 37%-75%). The overall
outcomes varied based on the subtype of lymphoma: pa-
tients with ALCL had the best outcomes (9/9 patients are
alive and disease free) while those with LL had the worst (1
/8 patients is alive and disease free). Relapsed/progressive
disease was the cause of death for all 7 of the LL patients who
died. Patients with other B-cell and T-cell lymphomas also
